Greenwich Lifesciences Inc reports results for the quarter ended March 31 - Earnings Summary
23/05/2025 22:01
Greenwich Lifesciences Inc GLSI.OQ reported a quarterly adjusted loss of 25 cents per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -19 cents. The lone analyst forecast for the quarter was for a loss of 24 cents per share. Reported revenue was zero; analysts expected zero. Greenwich Lifesciences Inc's reported EPS for the quarter was a loss of 25 cents. The company reported a quarterly loss of $3.26 million. Greenwich Lifesciences Inc shares had risen by 2.7% this quarter and lost 12.7% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 14.3% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Greenwich Lifesciences Inc is $39.00 This summary was machine generated from LSEG data May 23 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -0.24 | -0.25 | Missed |
| Dec. 31 2024 | -0.21 | -0.61 | Missed |
| Sep. 30 2024 | -0.21 | -0.20 | Beat |
| Jun. 30 2024 | -0.20 | -0.20 | Met |
Recent news on Greenwich Lifesciences
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Greenwich Lifesciences Inc reports results for the quarter ended June 30 - Earnings Summary
Greenwich Lifesciences Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: Greenwich Lifesciences Announces Approval To Expand FLAMINGO-01 Into The United Kingdom
U.S. STOCKS ON THE MOVE-Yum Brands, AMD, Nuvation Bio